MedTrace Logo

Stem Cell Ophthalmology Treatment Study

NCT01920867 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-10-23

No results posted yet for this study

Summary

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease. http://mdstemcells.com/scots-ii/

Conditions

  • Retinal Disease
  • Macular Degeneration
  • Hereditary Retinal Dystrophy
  • Optic Nerve Disease
  • Glaucoma

Interventions

PROCEDURE

RB (Retrobulbar)

Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)

PROCEDURE

ST (Subtenon)

Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)

PROCEDURE

IV (Intravenous)

Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)

PROCEDURE

IVIT (Intravitreal)

Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)

PROCEDURE

IO (Intraocular)

Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.

Sponsors & Collaborators

  • MD Stem Cells

    lead INDUSTRY

Principal Investigators

  • Steven Levy, MD · MD Stem Cells

  • Jeffrey Weiss, MD · MD Stem Cells

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01920867 on ClinicalTrials.gov